JAZZ) today announced financial results for the fourth quarter and full year ended. Total revenues for 2008 included contract revenue of $1.1 million, compared to $10.6 million for 2007, which included $9.5 million of milestone payments from UCB Pharma Limited. Announces Fourth Quarter and Full Year 2008 Financial Results PALO ALTO, Calif., / - / -- Jazz Pharmaceuticals, Inc. Net sales of once-daily LUVOX CR(R) (fluvoxamine maleate) Extended-Release Capsules, launched in were $3.1 million for.

XYREM(R) (sodium oxybate) oral solution net sales increased 42% to $15.8 million for the quarter ended , compared to sales of $11.1 million for the quarter ended. A $10.0 million milestone payment received in 2008 from UCB Pharma Limited will be recorded as contract revenue in 2009.

XYREM net sales for the year ended increased 38% to $53.8 million, compared with $39.0 million for the year ended. Total revenues for the quarter ended were $19.6 million, compared to $15.5 million for the quarter ended.

Total revenues for the year ended were $67.5 million, compared to $65.3 million for the year ended.